Wednesday, Apr 23rd

Last update10:59:28 AM GMT






You are here: News BioMedTech

Cambridge cancer firm lines up $174m bonanza

Sentinel-Bob-BoyleMedical technology from Cambridge UK cancer business Sentinel Oncology is being developed and commercialised by US company Oncothyreon in a collaboration that could bring the Science Park firm mega-millions.

£150bn AstraZeneca-Pfizer merger mooted

Shaun-Grady - Astrazenca VPUK pharma company AstraZeneca, which is set to bring 2,000 jobs to the Cambridge medical technology cluster by 2016, has rejected a takeover approach from global heavyweight Pfizer.

Cambridge experts fight diabetes depression

Professor-khalida-IsmailA Cambridge healthcare technology business has won UK government funding to determine whether its online psychology solutions can help fight diabetes distress.

Cambridge Consultants fast-tracks global growth

Ambuj-JainCambridge Consultants has accelerated growth plans for its drug delivery device development business in India following major expansion in the UK and United States.

Cambridge-US antibodies alliance

Polytherics-John-BurtPolyTherics, which owns Antitope Ltd at Babraham Research Park, Cambridge UK has extended a collaboration with US biotech MacroGenics Inc designed to produce novel antibody drug conjugates.

Napp debuts in profits of boom table

NappNapp Pharmaceuticals in Cambridge makes its debut this weekend in The Sunday Times BDO Profit Track 100 league table.

Cambridge seven claim share of healthcare millions

Karen-LivingstoneSeven companies from the Cambridge medical technology cluster have won a share of £12.7 million funding from SBRI healthcare in a UK government backed programme.

Horizon opens up a new world of research capability

Eric Rhodes of Horizon DiscoveryHorizon Discovery has broadened its technology range to give life scientists a broader base of research tools.

Cambridge breakthrough in life limiting diseases

Dr Eddy Littler, CEO of DomainexDomainex, a medical technology business anchored in Cambridge UK, reports a breakthrough in a salvo of studies seeking new treatments in life-limiting diseases.

Crescendo takes Series A to $32.5m climax

Babraham Research Campus - thriving environment for Crescendo BiologicsCambridge UK medical technology business Crescendo Biologics has hoisted its Series A financing to a new high of $32.5 million after EMBL Ventures invested $3.3M in a final close.

Cambridge and Norwich get funding for DNA hothouses

David-WillettsThe Cambridge medical technology cluster and Norwich’s growing science segment are at the heart of a £12 million government initiative to give the genomics revolution a boost with the creation of new, dedicated DNA research hothouses.

Cambridge technology in Novartis auto-injector for MS

the ExtaviPro 30G auto-injectorBig Pharma giant Novartis is using medical technology expertise from Cambridge UK for a new auto-injector for sufferers of multiple sclerosis.

Vernalis closes in on cough cold NDA filing

Ian-Garland VernalisCambridge UK medical technology business Vernalis has posted annual results ahead of market expectations and further progressed its portfolio of cough cold drugs.

Activ8rlives at Gadget Show Live with new health monitors

Activ8rlivesA new generation of self-monitoring healthcare devices is being showcased in a Cambridge technology cluster company’s debut at the Gadget Show Live in the UK from April 9-13.

AstraZeneca and MRC open Cambridge disease research hothouse

Mene-PangalosA globally gamechanging disease research hothouse is being opened in the Cambridge UK technology cluster by AstraZeneca and the Medical Research Council.

New CEO heads Regenerys commercial drive

Dr Amr-AbidRegenerative medicines technology business Regenerys Ltd, which recently opened offices in Cambridge UK, has appointed a big-hitting CEO to drive a fresh phase of growth.

  • «
  •  Start 
  •  Prev 
  •  1 
  •  2 
  •  3 
  •  4 
  •  5 
  •  6 
  •  7 
  •  8 
  •  9 
  •  10 
  •  Next 
  •  End 
  • »

Page 1 of 56